New Target for Lymphoma Therapy

[Guest guest]

Greetings,

The rate of discovery - identifying key genetic switches which

drive lymphomas - continues to accelerate.

I would take the wager --- particularly if we can solve the

clinical trial participation problem -- that we will be curing

virtually all lymphomas before the end of the new decade.

Wishing all a bright and fullfilling New Year.

Karl

=

New Target for Lymphoma Therapy

ScienceDaily (Dec. 30, 2009) - Researchers at the Program in

Cellular and Molecular Medicine and the Immune Disease Institute

at Children's Hospital Boston (PCMM/IDI) have found a link

between a common mutation that can lead to cancer and a distant

gene regulator that enhances its activity.

The new study, published in the Dec. 10 issue of Nature,

identifies this regulatory component, and marks the first time

researchers are able to understand how this movement of genes,

or " chromosomal translocation, " can hijack a B cell's operation

badly enough to lead to cancer.

The study suggests the IgH3'RR as a new target for arresting

lymphomas and other blood-related cancers that arise from mature

B cells. Though inactivating IgH3'RR can impair a B cell's

versatility in creating different classes of antibodies, it

would not leave a patient immune-deficient because the B cells

would retain some of their activity, says Gostissa. Furthermore,

such a treatment would be reversible.

full text: http://bit.ly/5i8pmc

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm